Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future

British journal of clinical pharmacology

Volumn 78, Issue 4, 2014, Pages 699-706

  Kwong, Tsong Q iang ^a   Mohamed, Moin ^a  

^a EASTBOURNE DISTRICT GENERAL HOSPITAL   (United Kingdom)

Author keywords

eye; retina; vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; HYBRID PROTEIN; MONOCLONAL ANTIBODY; RANIBIZUMAB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANTAGONISTS AND INHIBITORS; EYE DISEASES; HUMAN; LICENSING; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; BEVACIZUMAB; EYE DISEASES; HUMANS; LICENSURE; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84964314761     PISSN: None     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12371     Document Type: Review

References (0)